Inclusion Criteria:

• Signed informed consent
• Estimated GFR between 15-60 ml/min/1.73 m2
• Serum iPTH value between 50-300 pg/mL
• Corrected serum calcium level 8.0-10.0 mg/dL (2.0-2.5 mmol/L)
• Phosphorous level <= 5.2 mg/dL (1.68 mmol/L)
• Serum albumin >= 3.0 g/dL (30 g/L)

• Echocardiogram results of:

  • Females: LV ejection fraction >/= 50% and septal wall thickness between 12-15 mm; and,
  • Males: LV ejection fraction >/= 50% and septal wall thickness between 13-16 mm
• The subject must have been receiving optimal medical management of left ventricular hypertrophy (LVF) and CKD, including appropriate use of RAAS inhibitors (ACEi, ARB or aldosterone inhibitor) if indicated by the subject's medical condition. If the subject is receiving RAAS inhibitors the dose must have been stable for greater than one month prior to the Screening Period. However, the subject may have switched to different brands but at equivalent doses as determined by the study physician during the month prior to the Screening Period.
• Subject must have a technically adequate baseline cardiac MRI.

Exclusion Criteria:

• Subject has previously been on prescription-based vitamin D therapy within the four weeks prior to the Screening Period
• Subject has a history of an allergic reaction or significant sensitivity to paricalcitol or to drugs similar to the study drug
• Pregnant or lactating females
• Subject is expected to initiate renal replacement therapy within one year
• Subject is expected to receive a new or increased dose of RAAS inhibitor during the course of the study

• Subject has clinically significant coronary artery disease (CAD) within the previous 3 months, defined as one of the following:

  • Hospitalization for MI or unstable angina; or
  • New onset angina with positive functional study or coronary angiogram revealing stenosis; or
  • Coronary revascularization procedure

• Subject has major cardiac valve abnormality linked with LVH and/or diastolic dysfunction, defined as one of the following:

  • Aortic valve area <= 1.5 cm2 or a mean gradient of > 20 mm Hg; or
  • Regurgitation lesions; more than moderate mitral regurgitation or more than moderate aortic regurgitation
• Subject has asymmetric septal hypertrophy
• Subject has had a severe cerebrovascular accident (CVA) within the previous 3 months (e.g., hemorrhagic)
• Full remission from a malignancy for less than one year except completely excised non-Melanoma skin cancer or any history of bone metastasis
• Subject has co-morbid conditions (e.g., advanced malignancy, advanced liver disease) with a life expectancy less than 1 year
• Subject has received any investigational drug within 30 days prior to study drug administration or is currently enrolled in another clinical trial
• Subject has a history of active kidney stones within the previous 2 years
• Subject has poorly controlled hypertension
• Subject has history of renal artery stenosis, primary aldosteronism or pheochromocytoma
• Subject is taking calcitonin, bisphosphonates, cinacalcet, glucocorticoids (except topical or inhaled glucocorticoids)
• Subject is currently receiving immunosuppressant therapy and/or high doses (non-maintenance therapy) of steroids
• Subject has had acute renal failure within the previous 12 weeks
• Subject is known to be HIV positive
• Use of known inhibitors or inducers of cytochrome P450 3A (CYP3A) within two weeks prior to study drug administration
• Subject is contraindicated for MRI examination
• Investigator considers subject unsuitable for any reason
• Subject has a history of drug or alcohol abuse within six months prior to Screening
• Subject weighs more than 340 pounds (154 kilograms)
• Subject has had a liver or kidney transplant